GCP
NAUT icon

Gill Capital Partners’s Nautilus Biotechnolgy NAUT Stock Holding History

Gill Capital Partners’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$468 Hold
250
– – ﹤0.01% 648
2026
Q1 		$970 Buy
+250
New +$614 ﹤0.01% 600

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Gill Capital Partners's NAUT Position: Q2 2026 in Review

Gill Capital Partners held its Nautilus Biotechnolgy (NAUT) position steady in Q2 2026 at 250 shares worth $468. The position accounts for ﹤0.01% of the portfolio, ranked #648.

Gill Capital Partners first reported a position in NAUT in Q1 2026 and has held it in 2 quarters since. The position peaked at $970 in Q1 2026. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • Gill Capital Partners held 250 shares of Nautilus Biotechnolgy worth $468 as of Q2 2026.
  • Gill Capital Partners left its Nautilus Biotechnolgy share count unchanged in Q2 2026.
  • Nautilus Biotechnolgy made up ﹤0.01% of Gill Capital Partners's portfolio in Q2 2026, its #648 holding.
  • Gill Capital Partners first reported a position in Nautilus Biotechnolgy in Q1 2026 and has held it in 2 quarters since.
  • Gill Capital Partners's Nautilus Biotechnolgy position peaked at $970 in Q1 2026.
  • 93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Gill Capital Partners's 13F filing for Q2 2026, filed 20 Aug 2026.